From bench to clinic and back: Perspective on the 1stIQPC Translational Research conference

被引：31

作者：

Hörig H. ^{[1
]}

Pullman W. ^{[2
]}

机构：

[1] Columbia University Medical Center, Division of Surgical Science, Columbia

[2] Sanofi-Aventis, Bridgewater

来源：

Journal of Translational Medicine | / 2卷 / 1期

关键词：

Translational Research; Cancer Vaccine; Surrogate Endpoint; Fine Needle Aspirate; Tumor Bank;

D O I：

10.1186/1479-5876-2-44

中图分类号：

学科分类号：

摘要：

Translational Research (TR) provides a set of tools and communication context for scientists and clinicians to optimize the drug discovery and development process. In the proceedings of a Princeton conference on this timely topic, the strengths and needs of this developing field were debated. Outcomes and key points from these discussions are summarized in this article which covers the topics of defining what we mean by translational research (both theoretically and in operational terms), ways in which to engender the TR mindset and embed it in organizations such as the pharmaceutical industry in order to optimize the impact of available technologies (including imaging methods), the scientific basis and under-pinnings of TR including genomics knowledge, information sharing, as well as examples of application to drug discovery and development. Importantly, it should be noted that collaborations and communications between the stakeholders in this field, namely academia, industry and regulatory authorities, must be strengthened in order for the promise of TR to be delivered as better therapies to patients. © 2004 Hörig and Pullman; licensee BioMed Central Ltd.

引用

页数：8

共 14 条

[1]

Challenge and Opportunity on the Critical Path to new medical products, (2004)

[2]

Marincola F.M., Translational medicine: A two way road, J. Transl. Med., 1, (2003)

[3]

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework, Clin. Pharmacol. Ther., 69, pp. 89-95, (2001)

[4]

Boyle E.I., Weng S., Gollub J., Jin H., Botstein D., Cherry J.M., Sherlock G., GO: TermFinder - Open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes, Bioinformatics, 20, pp. 3710-3715, (2004)

[5]

Leung S.Y., Chen X., Chu K.M., Yuen S.T., Mathy J., Ji J., Chan A.S., Li R., Law S., Troyanskaya O.G., Tu I.P., Wong J., So S., Botstein D., Brown P.O., Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis, Proc. Natl. Acad. Sci. U. S. A., 10, 99, pp. 16203-16208, (2002)

[6]

Wang E., Adams S., Zhao Y., Panelli M., Simon R., Klein H., Marincola F.M., A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides applicable in the clinical settings, J. Transl. Med., 1, (2003)

[7]

Panelli M.C., White R., Foster M., Martin B., Wang E., Smith K., Marincola F.M., Forecasting the cytokine storm following systemic interleukin-2 administration, J. Transl. Med., 2, (2004)

[8]

Monsurro V., Wang E., Yamano Y., Migueles S.A., Panelli M.C., Smith K., Nagorsen D., Connors M., Jacobson S., Marincola F.M., Quiescent phenotype of tumor-specific CD8+ T cells following immunization, Blood, 104, pp. 1970-1978, (2004)

[9]

Vakkila J., Lotze M.T., Inflammation and necrosis promote tumour growth, Nat. Rev. Immunol., 4, 8, pp. 641-648, (2004)

[10]

Lotze M.T., DeMarco R.A., Dealing with death: HMGB1 as a novel target for cancer therapy, Curr. Opin. Investig. Drugs, 4, 12, pp. 1405-1409, (2003)

← 1 2 →